血栓形成伴血小板减少综合征:Ad26.COV2.S临床试验与上市后经验的数据库综述
该研究对Ad26.COV2.S临床试验和全球医学安全数据库中血栓形成伴血小板减少的病例进行描述性数据库综述。临床试验中Ad26.COV2.S接种者发生34例(46/10万人年),安慰剂组15例(75/10万人年)。全球医学安全数据库有355例自发报告,其中27例符合所有定义的最高诊断确定性,8例死亡。结论认为Ad26.COV2.S诱导的TTS非常罕见,多数并存血栓形成伴血小板减少不构成TTS。
要点
- 临床试验中Ad26.COV2.S接种者血栓形成伴血小板减少发生率为46/10万人年,安慰剂组为75/10万人年。
- 全球医学安全数据库355例自发报告中,85%发生在接种后28天内,8例死亡。
- 作者结论认为Ad26.COV2.S诱导的TTS非常罕见,多数并存血栓形成伴血小板减少不构成TTS。
核心结论
- Ad26.COV2.S诱导的TTS非常罕见,多数并存血栓形成伴血小板减少不构成TTS。
研究设计与样本
- 对Ad26.COV2.S临床试验参与者及真实世界临床实践中接种Ad26.COV2.S后42天内发生血栓形成伴血小板减少的所有病例进行描述性数据库综述,病例来自Janssen临床试验和全球医学安全数据库。
主要发现
- 临床试验中Ad26.COV2.S接种者发生34例血栓形成伴血小板减少(46/10万人年),安慰剂组15例(75/10万人年)。
- Ad26.COV2.S接种者中,事件发生时平均年龄63岁(范围25-85),82%为男性,末次接种后至发病平均112天(范围8-339),26例发生在第1剂后,7例发生在接种后28天风险窗内。
- 采用Brighton Collaboration、美国疾病控制与预防中心和欧洲药品管理局药物警戒风险评估委员会病例定义评估诊断确定性,1例符合所有3个定义的最高诊断确定性水平。
- 全球医学安全数据库有355例血栓形成伴血小板减少自发报告,47%为男性,85%在接种后28天内;27例符合所有定义的最高诊断确定性,其中21例女性,19例脑静脉窦血栓形成,年龄范围18-68岁;20例发病时间为接种后7-14天;8例死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thrombosis with thrombocytopenia syndrome (TTS) is a very rare disorder described after vaccination with adenoviral vector-based COVID-19 vaccines. Co-occurring thrombosis with thrombocytopenia reported after vaccination can be a proxy for identification of TTS. METHODS: Descriptive database review of all cases of co-occurring (within 42 days) thrombosis with thrombocytopenia in participants in Ad26.COV2.S clinical trials or recipients of Ad26.COV2.S in real-world clinical practice. Cases were retrieved from Janssens' clinical trial and Global Medical Safety databases. RESULTS: There were 34 cases of co-occurring thrombosis with thrombocytopenia in Ad26.COV2.S recipients (46 per 100,000 person-years) and 15 after placebo (75 per 100,000 person-years) in clinical trials. Among Ad26.COV2.S recipients, mean age at the time of the event was 63 years (range 25-85), 82 % were male, mean time-to-onset 112 days (range 8-339) post-last Ad26.COV2.S dose, 26 events occurred post-dose-1, and 7 within a 28-day risk window post-vaccination. Diagnostic certainty was evaluated using Brighton Collaboration, US Centers for Disease Control and Prevention, and European Medicines Agency Pharmacovigilance Risk Assessment Committee case definitions. One case met the highest level of diagnostic certainty for all 3 definitions. There were 355 spontaneous reports of co-occurring thrombosis with thrombocytopenia in the Global Medical Safety database, 47 % males, 85 % within 28-days after vaccination. Twenty-seven cases met the highest level of diagnostic certainty for all definitions, 21 female, 19 with cerebral venous sinus thrombosis, age-range 18-68 years. Time-to-onset was 7-14 days post-vaccination in 20 cases. There were 8 fatalities. CONCLUSION: TTS induced by Ad26.COV2.S is very rare. Most co-occurring thrombosis with thrombocytopenia does not constitute TTS.
引用
- Struyf F, Hardt K, Van Rampelbergh R, et al. Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S. Vaccine. 2023. PMID: 37517912. doi:10.1016/j.vaccine.2023.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。